Valuation : Noxopharm Limited

Market Cap 26.73M 19.14M 16.48M 15.48M 14.13M 26.54M 1.82B 183M 71.35M 924M 71.88M 70.32M 3.06B P/E 2024
-5.39x
P/E 2025 -3.23x
Enterprise Value 27.65M 19.81M 17.05M 16.01M 14.62M 27.46M 1.88B 190M 73.82M 956M 74.36M 72.75M 3.16B EV / Sales 2024
7.07x
EV / Sales 2025 5.92x
Free-Float
71.75%
Yield 2024 *
-
Yield 2025 -
1 week-3.26%
Current month+8.54%
1 month+8.54%
3 months+4.71%
6 months+30.88%
Current year-4.30%
1 week 0.08
Extreme 0.082
0.1
1 month 0.08
Extreme 0.076
0.1
Current year 0.05
Extreme 0.051
0.11
1 year 0.05
Extreme 0.051
0.11
3 years 0.03
Extreme 0.033
0.16
5 years 0.03
Extreme 0.033
0.6
10 years 0.03
Extreme 0.033
1.8
Manager TitleAgeSince
Chief Executive Officer - 2026-04-14
Director of Finance/CFO - 2019-02-28
Corporate Officer/Principal - 2017-12-31
Director TitleAgeSince
Chairman 70 2016-03-14
Director/Board Member - 2020-03-25
Chairman 71 2020-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/20/23 Buy

Chairman

880 0.0003%
9/17/23 Buy

Chairman

253,001 0.0866%
7/3/23 Buy

Chairman

135,281 0.0463%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.26%-15.24%+154.29% 19.58M
+0.17%-1.63%+1.26%+18.27% 49.81B
-1.11%-2.84%+420.04%+505.15% 44.06B
-0.21%+0.37%+36.88%+17.32% 42.99B
-1.95%-3.33%+8.29%+73.25% 40.88B
-0.94%-1.77%+18.34%+46.84% 33.11B
-1.11%-4.20%+25.49%+119.78% 16.58B
+6.10%+4.40% - - 17.27B
+0.80%-1.30%+12.53%+29.10% 14.63B
-1.12%-3.46%+76.50%+39.37% 13.76B
Average +0.06%-1.56%+64.90%+111.48% 27.31B
Weighted average by Cap. -0.28%-1.50%+88.96%+122.78%

Financials

2024 2025
Net sales 2.4M 1.72M 1.48M 1.39M 1.27M 2.38M 164M 16.47M 6.41M 82.94M 6.45M 6.31M 275M 2.82M 2.02M 1.74M 1.63M 1.49M 2.8M 192M 19.35M 7.53M 97.47M 7.59M 7.42M 323M
Net income -3.58M -2.56M -2.21M -2.07M -1.89M -3.55M -244M -24.55M -9.55M -124M -9.62M -9.41M -409M -4.88M -3.5M -3.01M -2.83M -2.58M -4.85M -333M -33.51M -13.04M -169M -13.13M -12.85M -559M
Net Debt -2.32M -1.66M -1.43M -1.34M -1.23M -2.3M -158M -15.92M -6.19M -80.16M -6.24M -6.1M -265M 925K 662K 570K 536K 489K 918K 63.03M 6.35M 2.47M 31.96M 2.49M 2.43M 106M
Logo Noxopharm Limited
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
Employees
-
Date Price Change Volume
26-08-31 A$0.0890 0.00% 123,298
26-08-31 A$0.0890 +5.95% 4,873
26-08-28 A$0.0840 -6.67% 51,074
26-08-27 A$0.0900 -2.17% 10,775
26-08-26 A$0.0920 -3.16% 20,491